*September 2019 – for immediate release Further information: Chris Pockett, +44 1453 524133*

**Renishaw promotes robotic stereoelectroencephalography (SEEG) at ILAE**

From 2-4 October 2019, global engineering technologies company, [Renishaw](https://www.renishaw.com/en/medical-and-healthcare--32082?utm_source=StoneJunction&utm_medium=Hard%20news&utm_content=REM159), is attending the International League Against Epilepsy’s (ILAE) Annual Scientific Meeting. Attendees can visit Renishaw’s stand to find out more about the benefits of robotic SEEG. The conference will take place in The Birmingham Conferences & Events Centre, Birmingham, UK.

Surgeons can use Renishaw’s *neuromate*®stereotacticrobot to perform SEEG, a procedure used to identify potential epileptogenic foci, where multiple intracerebral electrodes are inserted into the brain along pre-planned trajectories. Once the surgeon has identified the epileptogenic region using SEEG, they can then decide on future action, which might include excision or ablation.

The robot is currently in use in all of NHS England’s Children’s Epilepsy Surgery Service centres. Alongside the robot, Renishaw also provides *neuroinspire*™ software for surgical planning, to help determine the safest surgical route and visualise the implants in position.

Renishaw is also the exclusive UK and Ireland distributor for DIXI medical, and can supply a full range of SEEG electrodes for the exploration, functional mapping and thermocoagulation of epileptic foci.

“Epilepsy surgery is increasingly being recognised as a way to relieve the burden of seizures in certain cases,” explained Stuart Campbell, Clinical Sales Development Manager for Renishaw’s Neurological Products Division. “In children, early surgical intervention can minimise the risk of negative developmental and psychosocial outcomes or other long-term effects.”

“The *neuromate* robot has been safely used in thousands of procedures to provide a consistent, rapid and precise platform,” added Campbell. “Renishaw is a complete supplier of products for SEEG, offering the robot, software, SEEG electrodes, accessories and training required for the procedure, so that surgeons, neurologists and neurophysiologists have everything they need to benefit their patients.”

The ILAE’s Annual Meeting has been run in the UK every year since 1913. This year’s event features a broad programme ranging from basic neurobiology to clinical epileptology and social care, to appeal to the organisation’s broad membership base. It includes the presentation of clinical and experimental science to educate the community.

For further information on Renishaw’s neurological products and systems, visit [www.renishaw.com/neuro](http://www.renishaw.com/neuro).

**-ENDS-**

**Notes to editors**

UK-based Renishaw is a world leading engineering technologies company, supplying products used for applications as diverse as jet engine and wind turbine manufacture, through to dentistry and brain surgery. It has 5,000 employees located in the 36 countries where it has wholly owned subsidiary operations.

For the year ended June 2019 Renishaw recorded sales of £574 million of which 94% was due to exports. The company’s largest markets are the USA, China, Japan and Germany.

Throughout its history Renishaw has made a significant commitment to research and development, with historically between 13 and 18% of annual sales invested in R&D and engineering. The majority of this R&D and manufacturing of the company’s products is carried out in the UK.

The Company’s success has been recognised with numerous international awards, including eighteen Queen’s Awards recognising achievements in technology, export and innovation.

Further information at [www.renishaw.com](https://renishawplc-my.sharepoint.com/personal/lp138190_renishaw_com/Documents/www.renishaw.com)